- Received IMPD Approval to Commence Enrollment in France for Pivotal Phase 3 Study of Galinpepimut-S in Acute Myeloid Leukemia Patients - - Strengthened Balance Sheet During Quarter with $9.2 Million Financing - NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or… Read More..
Certain assays under development are believed to be the first ever for use at the point-of-care and the first ever available in veterinary medicine ANN ARBOR, Mich., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs… Read More..
CUPERTINO, CA / ACCESSWIRE / November 12, 2020 / Aemetis, Inc. (NASDAQ:AMTX), an advanced renewable fuels and biochemicals company innovating the reduction of carbon intensity, today announced its financial results for the three and nine months ended September 30, 2020. Aemetis' third quarter of 2020 included significant announcements and financial achievements: Ethanol… Read More..